Gaelic Laboratories and Athlone Laboratories are strengthening Ireland’s antibiotic manufacturing capacity through a dual-source model for oral Beta-Lactam products, allowing customers to source the same medicines from either of two Irish manufacturing sites.

The development follows Gaelic Laboratories’ acquisition of Athlone Laboratories in December 2025, bringing together two GMP-approved manufacturers specialising in oral-dose Beta-Lactam products. Since the acquisition, the companies have been integrating supply chains and administrative systems while aligning IT, compliance and operational processes under a joint operating model.

As reported by Manufacturing Chemist, the next phase has focused on aligning manufacturing operations and technology-transfer processes so products can be produced consistently across both facilities. Both sites are being upgraded to meet the latest AMR Industry Alliance Manufacturing Standard, while strengthened technology-transfer protocols are intended to support consistent production between locations.

The combined operation has an annual capacity of 1.2 billion oral dosage forms, serving customers across Ireland, the UK, EU, MENA, Canada and Australia. The companies will showcase the dual-source model at CPHI Milan, running from 6 to 8 October 2026, where they will exhibit on stand 12A59 in Hall 12. CPHI’s company listing confirms Gaelic Laboratories’ participation.

For Ireland’s pharmaceutical manufacturing sector, the development highlights the potential of consolidation to create greater operational resilience. The two businesses are bringing their manufacturing facilities, technical capabilities and workforce into a more closely integrated model, creating additional capacity while maintaining a common approach to quality and compliance.

The dual-site model also gives pharmaceutical customers an alternative to single-facility sourcing. Having aligned manufacturing capability at two locations can provide greater continuity if production at one site is affected by maintenance, capacity constraints or other operational requirements, while allowing customers to remain within the same supplier network.

For the sector, the Gaelic-Athlone integration shows how an acquisition can create value beyond increased scale. By aligning manufacturing standards, technology transfer and operational processes, the companies are building a multi-site platform that strengthens supply continuity while giving an Irish manufacturer greater capacity to serve international antibiotic markets.

Source: Manufacturing Chemist / Gaelic Laboratories / CPHI